Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Total 13F shares
-
13,758,120
-
Share change
-
+13,643,120
-
Total reported value
-
$198,361,725
-
Price per share
-
$14.50
-
Number of holders
-
31
-
Value change
-
+$196,693,691
-
Number of buys
-
30
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q1 2016
As of 31 Mar 2016,
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,758,120 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Novo A/S, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, JENNISON ASSOCIATES LLC, Rock Springs Capital Management LP, SCOPIA CAPITAL MANAGEMENT LP, CREDIT SUISSE AG/, Alyeska Investment Group, L.P., and Allianz Asset Management AG.
This page lists
31
institutional shareholders reporting positions in this security
for the Q1 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.